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Abstract
Advanced glycation end-products (AGEs) are increased and predict mortality in patients
with chronic kidney disease (CKD) who are undergoing hemodialysis, irrespective of the
presence of type 2 diabetes. However, little information exits about the relationship between
AGEs and subclinical atherosclerosis at the early stages of CKD. A case-control study was
performed including 87 patients with mild-to-moderate stages of CKD (glomerular filtration
rate from 89 to 30 ml/min/per 1.73m2) and 87 non-diabetic non-CKD subjects matched by
age, gender, body mass index, and waist circumference. Skin autofluorescence (AF), a
non-invasive assessment of AGEs, was measured. The presence of atheromatous disease
in carotid and femoral arteries was evaluated using vascular ultrasound, and vascular age
and SCORE risk were estimated. Patients with mild-to-moderate stages of CKD showed an
increase in skin AF compared with control subjects (2.5±0.6 vs. 2.2±0.4 AU, p<0.001). A
skin AF value >2.0 AU was accompanied by a 3-fold increased risk of detecting the pres-
ence of an atheromathous plaque (OR 3.0, 95% CI 1.4–6.5, p = 0.006). When vascular age
was assessed through skin AF, subjects with CKD were almost 12 years older than control
subjects (70.3±25.5 vs. 58.5±20.2 years, p = 0.001). Skin AF was negatively correlated with
glomerular filtration rate (r = -0.354, p<0.001) and LDL-cholesterol (r = -0.269, p = 0.001),
and positively correlated with age (r = 0.472, p<0.001), pulse pressure (r = 0.238, p =
0.002), and SCORE risk (r = 0.451, p<0.001). A stepwise multivariate regression analysis
showed that age and glomerular filtration rate independently predicted skin AF (R2 = 0.289,
p<0.001). Skin AF is elevated in patients with mild-to-moderate CKD compared with control
subjects. This finding may be independently associated with the glomerular filtration rate
and the presence of subclinical atheromatous disease. Therefore, the use of skin AF may
help to accurately evaluate the real cardiovascular risk at the early stages of CKD.
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Introduction
Advanced glycation end products (AGEs) characterize a heterogeneous group of compounds
formed by the non-enzymatic glycation of proteins after exposure to aldose sugars [1]. These
reactions progress in normal aging, and are accelerated under chronic hyperglycemia [2, 3]. In
this way, the concentration of AGEs is associated with a higher incidence and faster progres-
sion of chronic type 2 diabetes (T2D) microangiopathy, and it is also an independent predictor
of mortality in this population [4, 5]. In addition, other conditions like chronic inflammation,
oxidative stress, and tobacco smoke can lead to increased AGES formation [1, 6, 7].
The gold standard skin biopsy measurement of AGEs agglomeration may be substituted by
a non-invasive device based on skin autofluorescence (AF) [8]. Skin AF has been previously
validated in clinical settings, and its clinical value has been established in large studies includ-
ing individuals with a high risk of atherosclerosis, as T2D and chronic kidney disease (CKD)
[9–12]. AGEs promote the development and evolution of atherosclerosis through direct and
receptor pathways [13].
The progressive loss of glomerular filtration rate (GFR) is associated with systemic inflam-
mation, as well as with an imbalance between oxygen reactive species production and antioxi-
dant defenses [14, 15]. Increased circulating levels of AGEs are found in patients with CKD
undergoing hemodialysis regardless, of the presence of T2D [4, 16]. Some additional factors
have been associated with AGEs accumulation in renal failure because of decreased glomerular
filtration, intraperitoneal formation during the time course of peritoneal dialysis, or dietary
intake [17–20]. Therefore, the high body burden of AGEs in subjects with CKD may play a
role in the pathogenesis of vascular complications associated with hemodialysis [21]. However,
there is little information about the relationship between AGEs and subclinical atherosclerosis
at earlier stages of CKD.
To shed light on this issue, we performed a case-control study of tissue accumulation of
AGEs according to the presence of mild to moderate CKD. For this purpose, we selected sub-
jects without T2D and no previous cardiovascular events. The AGEs were measured via skin
AF. We also aimed to assess the relationship between AGEs accumulation and subclinical
atheromatosis, by evaluating vascular ultrasound data.
Material and Methods
Ethics statement
Informed written consent was obtained from all participants, and the protocol was approved
by the Arnau de Vilanova University Hospital ethics committee.
Design of the study and description of the study population
We assessed the effect of mild to moderate CKD on tissue accumulation of AGEs following the
Strengthening the Reporting of Observational Studies in Epidemiology guidelines for reporting
case-control studies [22].
A total of 128 patients attending the outpatient Nephrology Clinic were examined to deter-
mine eligibility at the time of a regular visit between December 2014 and October 2015. The
inclusion criteria were age older than 18 years, Caucasian origin, and GFR categories G2
(mildly decreased; 60–89 ml/min/per 1.73m2), G3a (mildly to moderately decreased; 45–59
ml/min/per 1.73m2), or G3b (moderately to severely decreased; 30–44 ml/min/per 1.73m2)
according the standards established by the Kidney Disease: Improving Global Outcomes [23].
Therefore, all patients with GFR category G2 also present moderately or increased albuminuria
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( 30 mg/g or 3 mg/mmol). The GFR was estimated following the CKD-EPI (Chronic Kid-
ney Disease Epidemiology Collaboration) equation [24].
Using the standard deviation of serum AGEs detected in a previous study, we determined
that the minimum sample required was 51 subjects [2]. Forty-one patients were excluded: T2D
(n = 10), prior cardiovascular event (n = 8), GFR lower than 30 ml/min/per 1.73m2 (n = 6),
non-Caucasian races (n = 4), chronic treatment with steroids (n = 3), active malignancy
(n = 3), type 1 diabetes (n = 3), and age older than 80 years (n = 1). Moreover, 3 patients were
excluded for their brown skin (Fitzpatrick type IV skin) because the excessive light absorption
produced by this type of skin precludes reliable measurements of skin AF. No pregnant
women were evaluated.
We aimed to select one control for every case. Subsequently, 87 subjects without kidney dis-
ease (GFR categories G1 and G2 without albuminuria) from the same Department served as
the control group. Controls were closely matched to cases by, gender, BMI, waist circumfer-
ence, and smoking status. As a linear relation between skin AF and subject age has been previ-
ously described, both groups were also matched by chronological age [2].
Measurement of AGEs accumulation and determination of vascular age
Skin AF was measured using the AGE Reader™ device (DiagnOptics, Groningen, The Nether-
lands), a fully automated noninvasive tool that measures AGE deposition using an Ultraviolet-
A spectrum. The skin AF is determined from the ratio between the emission fluorescence in
the wavelength range between 420–600 nm, and the reflected excitation light with a wave-
length between 300–420 nm, which was measured using a spectrometer and software. The
measurement time is about one minute, and the mean value of three readings was recorded in
all subjects. In addition, vascular age was calculated using skin AF value by the formula previ-
ously validated by Koetsier [vascular age = (skin AF– 0.83) / 0.024)] [2].
Vascular ultrasound study and SCORE risk estimation
The ultrasound assessment of carotid and femoral arteries followed a predetermined protocol
as defined in the NEFRONA study [25]. Briefly, B-mode and color-Doppler ultrasound imag-
ing was performed using a Vivid-i BT09device (General Electrics Healthcare, Waukesha, WI)
equipped with 6–13 MHz broadband linear array transducer and Doppler examinations in
transverse and longitudinal planes. The presence of atheromatous plaque in the following ter-
ritories was evaluated on the left and right sides: internal, bulb and common carotid arteries,
and deep and superficial femoral arteries. Plaques were defined as focal intrusions into the
lumen1.5 mm thick, as recommended by American Society of Echocardiography [26]. Simul-
taneously, the ankle-brachial index (ABI) was assessed: a pathologic ABI was defined as a value
0.9 or1.4, and the modified method by Schro¨eder was preferred [27]. Participants were clas-
sified by grades of atheromatous disease in 4 stages according ultrasound study and the ABI: (i)
no atherosclerosis (ABI>0.9); (ii) mild atherosclerosis (ABI between 0.7–0.9); (iii) moderate
atherosclerosis (carotid plaque with stenosis<50%); and (iv) severe atherosclerosis (ABI<0.7
or carotid plaque with stenosis50%) [25]. To better analyze our results, patients were grouped
according to the severity of atheromatous disease: Group I (patients without and with mild ath-
erosclerosis, in which the absence of plaques is mandatory) and Group II (patients with moder-
ate and severe atherosclerosis, in which presence of plaques is mandatory).
The SCORE (Systematic COronary Risk Evaluation) risk system is based on age, gender,
country of origin, systolic blood pressure, smoking status, and either total cholesterol or total
cholesterol/high-density lipoprotein cholesterol ratio. It was used to estimate the 10-year risk
of mortality from cardiovascular disease [28].
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Statistical analysis
Normal distribution of the variables was evaluated using the Kolmogorov-Smirnov test. Data
were expressed either as the mean ± SD or median (total range). Comparisons between groups
were performed using the Student’s t test or the Mann-Whitney U test for continuous vari-
ables, and the χ2 test or the Fisher test were used for categorical variables.
The relationship between the continuous variables was examined with Pearson’s linear cor-
relation test or the Spearman correlation coefficient. A stepwise multivariate regression analy-
sis was used to explore the variables independently related to skin AF. The independent
variables included age, gender, pulse pressure, LDL cholesterol, GFR, glycosylated haemoglo-
bin, and SCORE risk. Significance was considered with a two-sided p value <0.05. Statistical
analyses were performed using SSPS statistical package (SPSS, Chicago, IL, USA) version 20.
Results
The main clinical characteristics and metabolic data of the study population according to the
presence of CKD are showed in Table 1. Patients with mild to moderate decrease in GFR
showed significantly higher levels of skin AF versus non-CKD subjects (2.5 ± 0.6 vs. 2.2 ± 0.4
Table 1. Main clinical characteristics and metabolic data of the study population according to the presence of chronic kidney disease.
Mild to moderate CKD Non CKD Mean difference (95% CI) p
N 87 87 - -
Women, n (%) 33 (37.9) 33 (37.9) - 1.000
Age (yrs) 58.1 ± 10.6 56.5 ± 8.8 -1.5 (-4.4 to 1.4) 0.307
BMI (Kg/m2) 28.8 ± 5.8 28.9 ± 4.8 0.8 (-1.5 to 1.6) 0.918
Waist circumference (cm) 100.4 ± 15.1 100.7 ± 12.7 0.2 (-3.9 to 4.5) 0.893
Non-smoker, n (%) 56 (49.5) 49 (41.4) - 0.286
Systolic Blood Pressure (mm Hg) 131.1 ± 16.8 128.0 ± 18.0 -3.0 (-8.2 to 2.1) 0.246
Diastolic Blood Pressure (mm Hg) 77.6 ± 10.0 75.7 ± 11.7 -1.9 (-5.1 to 1.3) 0.253
Pulse Pressure (mm Hg) 53.5 ± 14.3 52.3 ± 14.3 -1.1 (-5.4 to 3.1) 0.591
Fasting plasma glucose (mmol/l) 5.3 ± 0.5 5.3 ± 0.8 0.0 (-3.1 to 4.7) 0.685
HbA1c (%) 5.4 ± 0.3 5.4 ± 0.4 0.0 (-0.1 to 0.1) 0.933
Serum Creatinine (mg/dL) 1.32 ± 0.6 0.81 ± 0.1 -0.5 (-0.6 to -0.3) <0.001
GFR (mL/min per 1.73m2) 60.8 ± 18.3 90.0 ± 9.3 29.1 (24.7 to 33.5) <0.001
ACR (mg/g) 108.2 ± 191.0 5.3 ± 5.3 -102.9 (-150.7 to -55.1) <0.001
Total cholesterol (mg/dL) 164.5 ± 35.6 194.9 ± 41.9 30.4 (-18.7 to 42.1) <0.001
HDL-cholesterol (mg/dL) 50.7 ± 12.6 53.2 ± 12.2 2.42 (-1.4 to 6.2) 0.218
LDL-cholesterol (mg/dL) 91.4 ± 27.9 117.4 ± 37.2 26.0 (15.8 to 36.3) <0.001
Triglycerides (mg/dL) 133.5 (42.0 to 780.0) 140.0 (52.0 to 632) 6.4 (-21.6 to 34.6) 0.650
SCORE risk (%) 2.3 ± 2.6 1.7 ± 2.2 -0.6 (-1.3 to 0.0) 0.079
Atheromatous plaque, n (%) 68 (78.1) 72 (82.7) - 0.444
Causes of chronic kidney disease
High blood pressure 36 (41.4) - - -
Polycystic kidney disease 16 (18.4) - - -
Glomerulonephritis 25 (28.7) - - -
Tubulointerstitial nephritis 10 (11.5) - - -
Data are means ± SD, n (percentage) or median (total range). CKD: chronic kidney disease; BMI: body mass index; HbA1c: glycosylated haemoglobin;
GFR: glomerular filtration rate estimated according the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation; ACR: albumin to
creatinine ratio; SCORE: Systematic Coronary Risk Evaluation.
doi:10.1371/journal.pone.0170778.t001
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arbitrary units (AU), p<0.001). When the subjects with and without atheromatous plaque
(group I vs. group II) were analyzed separately, differences in skin AF values persisted only in
the second group (Group II: 2.6 ± 0.5 vs. 2.2 ± 0.5 AU, p<0.001), and disappeared among sub-
jects with no detectable plaque (Group I: 2.2 ± 0.7 vs. 2.0 ± 0.3 AU, p = 0.464) (Fig 1). When
the entire population was evaluated, subjects with a skin AF value higher > 2.0 AU showed a
3-fold increased risk of an atheromathous plaque (OR 3.0, 95% CI 1.4–6.5, p = 0.006).
As shown in previous studies, a strong positive correlation was observed between skin AF
and age (r = 0.472, p<0.001), without differences between genders. While both groups were
closely matched for age, when vascular age was assessed, subjects with mild to moderate CKD
appeared to be almost twelve years older than control subjects (70.3 ± 25.5 vs. 58.5 ± 20.2
years, p = 0.001).
In the entire population, skin AF correlated negatively with GFR (r = -0.354, p<0.001), and
LDL-cholesterol (r = -0.269, p = 0.001), and correlated positively with age (r = 0.472,
p<0.001), pulse pressure (r = 0.238, p = 0.002), and SCORE risk (r = 0.451, p<0.001). (Fig 2).
The same linear correlations were observed when only patients with CKD were evaluated, but
disappeared in the control group. An intriguing negative correlation was also stablished
between AGEs and LDL cholesterol (Table 2).
Finally, a stepwise multivariate regression analysis showed that the age and GFR (but not
pulse pressure, glycosylated hemoglobin, LDL-cholesterol nor SCORE risk) were indepen-
dently associated with forearm skin AF (R2 = 0.289, p<0.001) (Table 3).
Discussion
To the best of our knowledge, this is the first study to show that subjects with early stages of
CKD significantly increase skin AF values. In addition, a close relationship exists between skin
AF and asymptomatic atheromatous disease in this population. Furthermore, skin AF appears
to be negatively correlated with GFR, suggesting that renal dysfunction is a key factor to
increase AGEs deposition in subcutaneous tissue.
The current study agrees with recent findings in subjects with an estimated GFR>60 ml/
min/per 1.73m2, in whom skin AF was significantly higher in those with peripheral artery dis-
ease versus the subclinical atherosclerosis group. This contributes to vascular damage in addi-
tion to classical mechanisms [29]. The biological effects of AGEs through its ligation to their
receptors located in large blood vessels accelerate plaque formation [13]. In patients with end-
stage renal disease, immunostained pentosidine -a major glycoxidation product- was observed
Fig 1. Skin autofluorescence according to the presence of atheromatous plaque between controls and
patients with mild to moderate stages of CKD. CKD: chronic kidney disease; AU: arbitrary units; *: p<0.001;
Group I: patients without and with mild atherosclerosis, in which the absence of plaques is mandatory; Group II:
patients with moderate and severe atherosclerosis, in which presence of plaques is mandatory.
doi:10.1371/journal.pone.0170778.g001
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along the elastin fibers in aortic media. This was associated with medial calcification [30].
These data also shown that deposition of AGEs accompanies subclinical atherosclerosis
beyond the presence of T2D [31].
Fig 2. Scatter plot showing linear correlation between skin autofluorescence and: pulse pressure,
and glomerular filtration rate. AU: arbitrary units; GFR: glomerular filtration rate estimated according the
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
doi:10.1371/journal.pone.0170778.g002
Table 2. Correlations of skin autofluorescence with clinic and metabolic variables.
All subjects Mild to moderate CKD Non CKD
r p r p r p
Age (yrs) 0.472 <0.001 0.586 <0.001 0.291 0.006
BMI (kg/m2) 0.040 0.600 0.088 0.417 -0.25 0.819
PP (mmHg) 0.238 0.002 0.380 <0.001 0.055 0.612
FPG (mmol/l) -0.021 0.789 0.016 0.885 -0.040 0.712
HbA1c (%) 0.054 0.603 0.139 0.307 -0.124 0.453
GFR (mL/min per 1.73m2) -0.349 <0.001 -0.315 0.003 -0.110 0.309
LDL-cholesterol (mg/dl) -0.269 0.001 -0.127 0.255 -0.284 0.011
SCORE risk (%) 0.451 <0.001 0.541 <0.001 0.314 0.105
CKD: chronic kidney disease; BMI: body mass index; PP: pulse pressure; FPG: fasting plasma glucose; HbA1c: glycosilated hemoglobin; GFR: glomerular
filtration rate estimated according the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation; SCORE: Systematic Coronary Risk
Evaluation).
doi:10.1371/journal.pone.0170778.t002
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CKD substantially increases the risk of cardiovascular disease. Indeed, a large community-
based population study including 1,120,295 adults showed an adjusted hazard ratio for cardio-
vascular events was 1.4 with an estimated GFR of 45 to 59 ml/min/per 1.73m2. This increased
to 2.0 with an estimated GFR of 30 to 44 ml/min/per 1.73m2 [32]. In addition, AGEs are also
known to accumulate in the microvasculature of the kidney and to promote glomerular filtra-
tion and proteinuria [33]. In fact, clinical studies in patients with type 1 diabetes revealed a sig-
nificant increase in the skin concentration of AGEs as urinary albumin increased from normal
to microalbuminuria, and macroalbuminuria [34].
The plasma concentration of AGEs in T2D has also identified those normoalbuminuric sub-
jects who will experience a higher increase in the glomerular basement membrane at in about
5-years follow-up period [35]. More recently, Luo et al. have demonstrated that in a non-hyper-
glycemic milieu, AGEs increase the permeability of the glomerular endothelial cells by a matrix
metalloproteinases degradation of tight junction complexes, mainly occluding and claudin-5 pro-
teins [36]. Our results support the close relationship between AGEs accumulation and decreases
in GFR because a strong and negative relationship between mild to moderate ranges of GFR and
skin AF was observed. Whether the AGEs renal accumulation in humans promotes kidney dys-
function or whether the decrease in GRF triggers AGE accumulation cannot be elucidated from
our study. However, when the receptor for AGEs is deleted in a mouse model, there is a 29%
increase in GFR accompanied by structural changes such as reduced thickening of glomerular
basement membrane and mesangial sclerosis [37].
When assessed using skin AF values, we observed a marked increase in vascular age, which
is more than 10 years higher than the chronological age in patients with CKD. Vascular aging
occurs along with endothelial dysfunction, vascular remodelling, inflammation, and increased
stiffness, all of them previously associated with AGEs [16, 38]. In this way, we observed a 3-fold
increased risk of an atheromathous plaque in subjects with a skin AF value higher> 2.0 AU.
This data support the idea that AGEs are useful in identifying a subclinical phenotype of early
vascular disease in large blood vessels [39]. Therefore, in a CKD population before end-stage
disease is established, skin AF may represent a clinically helpful and non-invasive method to
screen assess cardiovascular risk.
The relationship between skin AF and other conventional risk factors outside T2D remains
controversial. In our study, skin AF positively correlated with SCORE risk when the entire
population as well as patients with renal impairment were evaluated. However, the correlation
disappeared in the control group. Similarly, skin AF was not related to SCORE risk or its
Table 3. Stepwise multivariate regression analysis of variables associated with skin
autofluorescence.
Beta p
Skin AF Age (yrs) 0.424 <0.001
GFR (mL/min per 1.73m2) -0.275 <0.001
LDL-cholesterol (mg/dl) -0.148 0.112
SCORE risk (%) 0.155 0.171
PP (mmHg) 0.057 0.598
HbA1c (%) 0.032 0.719
R2 = 0.289 Constant 0.001
Beta: Standardized regression coefficient; AF: autofluorescence; GFR: glomerular filtration rate estimated
according the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation; SCORE
(Systematic Coronary Risk Evaluation); PP: pulse pressure; HbA1c: glycosilated haemoglobin.
doi:10.1371/journal.pone.0170778.t003
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components in a sub-study of the Groningen Overweight and Lifestyle (GOAL) project that
included overweight and obese subjects without T2D nor renal disease [40]. These data sup-
port the idea that, in the clinical setting the decreased GFR is as a key factor accounting for
skin AF when T2D is not present. The inverse association between skin AF and LDL choles-
terol detected in our population deserves an additional comment. When the LDL conjugated
diene is measured as marker of lipid peroxidative stress, a negative correlation with skin AF
has been described in critically ill patients [41]. In addition, serum LDL cholesterol was also
negatively correlated with skin AF in a cross-sectional study of 223 individuals visiting the vas-
cular outpatient clinic for primary or secondary prevention [29].
This study has some limitations. As a cross-sectional study, we cannot establish a causal
relationship between skin AF and subclinical atheromatosis. However, the problem is clinically
relevant since the prevalence of CKD reaches 20.4% among participants from the 2005–2006
National Health and Nutrition Examination Survey (NHANES), and help is needed to better
identify subjects at risk [42, 43]. Second, we did not compared skin AF with plasma AGEs lev-
els. We assumed that skin AF remains stable for a long time because it is less influenced by fac-
tors such as smoking or nutrition. In fact, plasma AGEs measurements were not different
when comparing individual with and without cardiovascular disease in participants from two
Dutch cohort studies including 1.291 subjects with various degrees of glucose metabolism
[44]. Third, skin AF could be unreliable in subjects with dark skin due to excessive light
absorption. We tried to solve this limitation selecting only Caucasian subjects and excluding
four of them with medium brown skin.
In conclusion, skin AF is elevated in patients with mild to moderate CKD in comparison
with control subjects. This finding is related with the presence of subclinical atheromatous dis-
ease, and appears to be independently associated with the GFR. Therefore, skin AF is an easy,
fast and non-invasive method that may help to accurately evaluate real cardiovascular risk in
the early stages of CKD.
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